All News

Article

AOSD: Young vs. Elderly Onset

Bella Mehta, MBBS, MS

Adult onset still's disease (AOSD) is an autoinflammatory condition characterized by fevers, arthritis, and rash. It is considered an orphan disease because of its low prevalence - it is reported anywhere between 16 to 40 per ten million.

Dr. John Cush Tweet
RheumNow
RheumNow’s expanded coverage of the #EULAR2023 meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its faculty.
David Liew Tweet
drdavidliew
75 different biosimilars in Europe, and nearly 20 years since the journey started. @EMA_News has led the world on biosimilars #EULAR2023 @RheumNow https://t.co/LFs3FR9dfW
Aurelie Najm Tweet
AurelieRheumo
Would you rather have Erosive hands OA or RA? 130+ EHOA and 370+ RA, dis duration > 10 yrs for both cohorts 📍EHOA associated w/ > pain & functional impairment 📍RA associated w/ > comorbidities @RheumNow #EULAR23 POS0103 https://t.co/KdDG7E6PZw
Aurelie Najm Tweet
AurelieRheumo
A model predicts development of PsA in PSO cohort at 1 yr w/ AUC 72.3 Risk factors: ✔️younger age ✔️male ✔️family hx of PSO ✔️back stiffness ✔️nail pitting, ✔️stiffness ✔️PGA ✔️bioDMARDs 5yr prediction model AUC 75 Promising but to be confirmed @RheumNow #EULAR23 POS0019 https://t.co/boCYOH2sDS
Aurelie Najm Tweet
AurelieRheumo
ANSWER cohort Retrospective study 6600+ bio/tsDMARDs ttmt courses, 20 yrs ✔️IL-6Ri is the lowest discontinued for lack of efficacy ✔️CTLA4-Ig is the lowest discontinued due to AEs ✔️Concomitant GC ⬆️30% drug discontinuation due to AEs @Rheumnow #EULAR23 POS0051 https://t.co/8e6U5KHmX4
Aurelie Najm Tweet
AurelieRheumo
The risk of osteoarticular infection following Staph aureus bacteremia is twice higher in RA (1/4) than non RA pop (1/8) Use of TNFi & orthopedic implants associated w/ OAI risk Mortality however similar in RA and non RA groups @RheumNow #EULAR23 POS0033 https://t.co/H6JYkbNu0B
David Liew Tweet
drdavidliew
Always great to have @EMA_News to come and to talk to us at #EULAR2023 Our meds are very important to us, and the more we can understand how decisions are made and RWE is collected, the better 👍 @RheumNow https://t.co/hSutraUsFD
Md Yuzaiful Md Yusof Tweet
Yuz6Yusof
#EULAR2023 #POS0112 Consistent with clinical response, Post-hoc analyses of Phase 2 RCT of Deucravacitinib (Tyk2-i) showed this therapy suppressed both IFN and B cell pathways - a broader mode of action in reducing #SLE pathophysiology. Look forward to Phase 3 results @RheumNow https://t.co/UoZ2xS3IzC
Aurelie Najm Tweet
AurelieRheumo
Can combined US examination of nail-enthesis complex & nailfold videocapillaroscopy differentiate PsA from PSO RA and HC? Brief answer is no, but: -PsA > tortuous capillaries vs. PSO & HC -Abnormalities in PSO to be used as predictor of PsA? TBC... @RheumNow #EULAR23 POS0025 https://t.co/RNbpht8QGh
Md Yuzaiful Md Yusof Tweet
Yuz6Yusof
#EULAR2023 #POS1147 Primary endpoint for Cenerimod (S1P1 modulator) phase 2 RCT in #SLE was not met after multiple testing. Post-hoc analysis showed greater reduction in SRI-4 and mSLEDAI in IFN-High vs IFN-Low at 6mths. A biomarker to stratify response in Phase 3 @RheumNow https://t.co/wKM5V1JgXT
Aurelie Najm Tweet
AurelieRheumo
Fluorescence optical imaging in early arthritis? Nice images but not ready for clinics yet Can not differentiate OA from RA & PsA SLE/SSc associated arthritis display a specific pattern, but usually auto-antibody profiles help w/ diagnosis OP0173 #EULAR23 @Rheunow https://t.co/bAMi9kDKS5
Dr. John Cush Tweet
RheumNow
JAK inhibitors have been effective in refractory inflammatory myositis, all open label, but no controlled trials. #EULAR2023
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×